Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient
In the summer of 2019, larotrectinib was approved as the first drug in Europe to be used in numerous different solid tumours if the tumour tissue displays a so-called NTRK gene fusion. Since such a fusion of a neurotrophic ...
Jan 16, 2020
0
1